Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
10/2008
10/08/2008EP1606283B1 P38 inhibitors and methods of use thereof
10/08/2008EP1597234B1 Novel compounds
10/08/2008EP1592675B1 Crystalline modifications of triazinylaminostilbenes
10/08/2008CN100424082C 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
10/08/2008CN100424080C Quinoxaline derivatives as neutrophil elastase inhibitors and their use
10/08/2008CN100424079C Bis-sulfonamides
10/07/2008US7432370 Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying
10/01/2008CN101274928A 3-substituted-4-pyrimidone derivatives
10/01/2008CN100422160C Novel morpholine derivatives, method for production thereof and pharmaceutical preparations containing said derivatives
10/01/2008CN100422157C Improved production of rosuvastatin calcium salt
10/01/2008CN100422151C Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
09/2008
09/30/2008US7429670 antagonists of the GlyR (glycine receptor); diterpene trilactones; cage-like skeleton; neuroprotectant, antioxidant, antiproliferation agent, cognition activator; parallel solution phase synthesis
09/30/2008US7429578 e.g. phenyl-3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5-(1H)-one; anticarcinogenic agent; stroke, head trauma, and neurodegenerative disease; potentiating cytotoxicity of a DNA-damaging cytotoxic agent or ionizing radiation
09/30/2008CA2417417C Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching
09/30/2008CA2355470C Benzoheterocycles and their use as mek inhibitors
09/25/2008US20080234481 Forming salts such as tartrate or mandelate ; chemical intermediate
09/23/2008US7427681 Anticancer agents; antidiabetic agents; Alzheimer's disease
09/23/2008US7427613 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
09/23/2008CA2432872C Pyrazole compounds useful as protein kinase inhibitors
09/17/2008EP1970374A1 Process for the production of substituted 2-(pyridin-2-ylmethylsulfinyl)-1H-benzimidazoles
09/17/2008EP1968971A1 Dioxolane derivates for the treatment of cancer
09/17/2008EP1409477B1 Piperidine derivatives as nmda receptor antagonists
09/17/2008CN101265262A New oxabispidine compounds useful in the treatment of cardiac arrhythmias
09/17/2008CN101265199A Method for the preparation of escitalopram
09/17/2008CN100418967C Tricyclic inhibitors of poly(ADP-ribose) polymerases
09/16/2008US7425560 Thioxanthine derivatives as myeloperoxidase inhibitors
09/16/2008CA2427221C Process and intermediates for preparing anti-cancer compounds
09/12/2008WO2004078116A9 P38 inhibitors and methods of use thereof
09/11/2008US20080221323 Production of Rosuvastatin Calcium Salt
09/11/2008US20080221178 Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof
09/11/2008US20080221065 Pharmaceutical formulations; epothilone and mannitol or a cyclodextrin parenteral administration in the form of an infusion concentrate or lyophilised composition
09/11/2008US20080220536 Tethering target having reactive thiol contacted with extender forming complex; conjugation; drug screening
09/11/2008US20080220002 Modified transferin-antibody fusion proteins
09/11/2008US20080216606 Grinding to uniform particle size; heating; pressurization;; extraction from ores, concentrates
09/10/2008CN101260072A Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
09/09/2008US7423049 e.g., 2-(5-fluoro-2-tolyl)-4-(4-aminocarbonylpiperazinylmethyl)-6-[a-aminocarbonyl-2,6-dichlorobenzyl]pyridine; mitogen-activated protein kinase inhibitor; antiinflammatory agent, autoimmune diseases
09/09/2008US7423041 e.g. 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility
09/09/2008CA2287881C Vitamin d3 analogs with bis c-20 side chains
09/04/2008US20080214824 Process for the Preparation of N-(4-Piperidinyl)-N-Ethyl-Phenylacetamides from N-Boc-4-Oxopiperidine
09/04/2008US20080214812 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
09/04/2008US20080214538 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics
09/03/2008EP1603909A4 Linear chain substituted monocyclic and bicyclic derivatives as factor xa inhibitors
09/03/2008CN100415737C Indole derivatives useful for treatment of CNS disorders
09/03/2008CN100415735C Amino alcohol derivatives
09/03/2008CN100415717C Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
09/02/2008US7420079 Intermediates for making 1(alpha-amino-1-(cyclopropyl-fused pyrrolidinylcarbonyl)methyl)-3-hydroxyadamantanes, e.g., methyl 3-hydroxy-<a-oxotricyclo[3.3.1.13,7]decane-1-acetate
09/02/2008US7420061 Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors
09/02/2008US7419990 e.g. benzyl {1-[2-(1-{[1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-4,5-dimethylphenyl]propyl}carbamate; antidiabetic agent, obesity, sexual disfunctions
09/02/2008CA2426956C Pharmaceutical compositions comprising ascomycin derivatives
09/02/2008CA2283126C Method for preparing 2-thienylethylamine derivatives
09/02/2008CA2273023C Aminoguanidines and alkoxyguanidines as protease inhibitors
08/2008
08/28/2008US20080207899 N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}methane-sulfonamide; trial and ventricular arrhythmias; pharmacokinetics; electrophysiological activity; lowering daily clinical dose, lengthening duration of action; side effect reduction
08/28/2008US20080207612 Analgesics; pain management
08/28/2008US20080206805 Compounds and Related Methods for Mutant p53 Reactivation
08/27/2008EP1622569A4 Aza spiro alkane derivatives as inhibitors of metallproteases
08/27/2008CN100413863C Novel 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for making same and pharmaceutical compositions containing same
08/27/2008CN100413860C Piperidine derivative as NMDA receptor antagonist
08/27/2008CN100413849C Benzimidazole derivatives
08/26/2008CA2432129C Pyrazole compounds useful as protein kinase inhibitors
08/21/2008US20080200460 Chemical Compounds
08/20/2008EP1670790B1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
08/20/2008EP1670770B1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof
08/20/2008EP1249233B1 Npyy5 antagonists
08/20/2008EP0883404B1 Combination therapy for osteoporosis
08/20/2008CN101245058A Inhibitors of aspartyl protease
08/20/2008CN101245043A Aza-heterocyclic compounds used to treat neurological disorders and hair loss
08/19/2008US7414056 Cytokine inflammatory response suppressors; mitogen activated protein 38 kinases
08/19/2008US7414045 Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors
08/19/2008CA2432799C Pyrazole compounds useful as protein kinase inhibitors
08/13/2008EP1956004A1 Quinoline derivatives and their use as 5-HT6 ligands
08/13/2008EP1678196B1 Sulfonylamino-peptidomimetics active on the somatostatin receptor subtypes 4 (sstr4) and 1 (sstr1)
08/13/2008EP1497290B1 Process for preparing acid salts of gemifloxacin
08/13/2008CN101239973A Substituted aminoquinazolinone (thione) derivative or salts thereof, intermediate compound therefor, pest-controlling agent and using method thereof
08/13/2008CN101239090A Pharmaceutical compositions having appetite suppressant activity
08/13/2008CN101239089A Pharmaceutical compositions having appetite suppressant activity
08/13/2008CN100410245C Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
08/12/2008US7411070 Form of S-omeprazole
08/12/2008US7410969 Antitumoral analogs of ET-743
08/07/2008US20080188518 5-Substituted Imidazoles
08/07/2008US20080188371 use as pesticides and/or herbicides and/or microbicides; for the selective control of weeds; synergistic; low application rates and concentrations; in particular in cereals (especially wheat)
08/06/2008EP1953142A1 Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives
08/06/2008CN100408573C Pyrazole compounds useful as protein kinase inhibitors
08/06/2008CN100408564C Pyrazole derivatives for treating HIV
08/06/2008CN100408026C Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same
08/05/2008US7408065 P2X7 receptor antagonists and their use
08/05/2008US7407981 e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; kinase inhibitor; obesity and stroke; diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia
08/05/2008US7407974 e.g. 4-Methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, thrombolytic agent; thrombus formation within blood vessels; cardiovascular disease
08/05/2008US7407972 e.g. 4,5-Dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; anticoagulant, thrombolytic agent; thrombus formation within blood vessels; cardiovascular disease
08/05/2008US7407956 Benzamide inhibitors of the P2X7 receptor
07/2008
07/31/2008US20080183007 Radical initiated coupling reaction between an alkylhalide and a hypophosphorous acid derivative; Bis-(trimethylsilyl)hypophosphite formed with trimethyl silyl chloride/diisopropyl ethylamine
07/31/2008US20080182874 e.g. 1-[6-Chloro-5-[(tricyclo[3.3.1.13,7]dec-1-ylacetyl)amino]-2-quinolinyl]-4piperidinecarboxylic acid; adamantyl-containing purinergic receptor P2X7 antagonists; antiinflammatory agent, immune or cardiovascular diseases; asthma, chronic obstructive pulmonary disease, rheumatoid arthritis
07/31/2008US20080182303 Enzymatic hydrolysis of lovastatin to form the triol acid; lactonization; regioselective acylation to form a 4-acetyl-protecting lactone; enzymatic acylation of the 8'-hydroxyl to form 4-acetyl simvastatin;selectively deprotecting to yield simvastatin; efficiency; nucleic acid-encoded hydrolases; kits
07/30/2008CN101230057A Method for the synthesis of a benzimidazole compound
07/30/2008CN100406459C 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
07/30/2008CN100406454C Pyrazole compounds useful as protein kinase inhibitors.
07/30/2008CN100406437C Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
07/29/2008US7405306 3-(2-alkoxycarbonyl-3-indolyl)-3-oxo-propionic acid ester or propionamide intermediates: methyl 3-[6-fluoro-2-(methoxycarbonyl)-1-methyl-1H-indol-3-yl]-3-oxopropanoate; peripheral neuropathy, Parkinson's disease, Alzheimer's disease
07/29/2008CA2432222C Pyrazole compounds useful as protein kinase inhibitors
07/29/2008CA2432132C Pyrazole compounds useful as protein kinase inhibitors
07/29/2008CA2333656C A novel vla-4 inhibitor: omepupa-v
1 ... 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ... 105